U.S. pharma bets big on China to snap up potential blockbuster drugs

japantimes.co.jp/business/2025/06/17/us-pharma-china-drugs

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar treatments.
Through June, U.S. drugmakers have signed 14 deals…

This story appeared on japantimes.co.jp, 2025-06-16 23:19:00.
The Entire Business World on a Single Page. Free to Use →